Neoplasm of immature B and T cells

Researchers are testing a CAR-T therapy called pCAR-19B in people with CD19-positive B-cell acute lymphoblastic leukemia that has relapsed or stopped responding to standard treatment. Participants receive an intravenous infusion of their own immune cells, which have been engineer…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This trial tests different ways to prepare children and adolescents with acute lymphoblastic leukemia for a stem cell transplant. The goal is to see whether a conditioning regimen without total body irradiation works as well as one with it, and to find the best approach for diffe…

This trial is testing whether combining anti-CD19 CAR-T cell therapy with the drug lenalidomide can safely and effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. Participants…

This trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…

This trial is testing whether a treatment plan tailored to each child's genetic risk can improve outcomes for relapsed acute lymphoblastic leukemia. Children and young adults up to age 22 whose leukemia has returned in the bone marrow receive a combination of chemotherapy drugs, …

This nationwide trial is testing whether adjusting chemotherapy intensity based on the amount of leukemia cells remaining after initial treatment (called minimal residual disease, or MRD) can improve outcomes for children and teens with high-risk acute lymphoblastic leukemia (ALL…

This phase 2 trial tests whether adding dasatinib and blinatumomab to standard chemotherapy can improve outcomes for children aged 1 to 19 with very high-risk acute lymphoblastic leukemia. The study focuses on patients with specific genetic markers or who did not respond to initi…

This trial tests whether using advanced genetic testing (NGS) to measure leftover cancer cells after initial treatment can help doctors tailor chemotherapy for children with standard-risk acute lymphoblastic leukemia. Around 116 children aged 1 to 10 will receive a standard chemo…

This large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This program gives patients with certain blood cancers access to Orca-T, a donor stem cell therapy, when the commercial version cannot be used. It is for people who have no other treatment options. The program monitors safety but does not test if the therapy works.

This Phase 2 trial tests a combination of two drugs, venetoclax and acalabrutinib, in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned after initial treatment with venetoclax plus an antibody. Participants first take acalabrutinib alone for 2 cycles, then a…

This phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…

This study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …

This early-phase trial tests whether giving anti-CD19 CAR T cells together with a half-matched bone marrow transplant can safely treat aggressive blood cancers like leukemia and lymphoma. About 155 adults aged 18 to 75 with CD19-positive cancers will receive the combined therapy …

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…

This study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a sin…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…

This phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…

This phase 3 trial compares starting treatment with venetoclax and obinutuzumab right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be randomly assigned t…

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem …

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This study tests a drug called binimetinib for people with hairy cell leukemia that does not have the common BRAF gene mutation. The drug targets a different gene, MEK, which is often altered in these patients. The goal is to see if it can shrink or control the cancer in 40 adult…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This early-phase trial tests a new treatment for hairy cell leukemia (HCL) that has come back or not responded to standard care. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. Up to 27 adults will receive chemo…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study tests whether daratumumab can eliminate tiny amounts of leukemia that remain after chemotherapy in people with T-cell acute lymphoblastic leukemia (T-ALL). About 20 adults whose cancer has come back or not fully cleared will receive the drug. The goal is to see if it c…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase trial is testing a combination of two drugs—Hyper-CVAD chemotherapy and venetoclax—in 22 children and young adults whose leukemia has returned or not responded to treatment. The main goal is to find a safe dose and monitor side effects. If the combination proves …

This study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…

This early-phase trial is testing whether a long-acting antibiotic called dalbavancin, given once every 28 days along with a short course of oral antibiotics, can prevent serious bloodstream infections in children and young adults with high-risk leukemia. The study will enroll 29…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-trea…

This phase II study is testing a combination of two drugs, enasidenib and azacitidine, in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial enrolls 50 adults with a specific IDH2 gene mutation. The goal is to see if the combinati…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study tests whether a non-invasive ventilation mask (NIPPV) can reduce the need for intubation in cancer patients with respiratory failure. Researchers will compare NIPPV plus standard oxygen therapy to standard oxygen therapy alone in 256 participants. The goal is to see if…

This phase 3 trial is testing a new oral drug, nemtabrutinib, against two standard targeted therapies (ibrutinib or acalabrutinib) in 1,200 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if nemtabrutinib works at least as well…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with two types of targeted therapy (BTK and BCL2 inhib…

This study tests a new type of CAR-T cell therapy, called UCD19 CAR-T, in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatment. The therapy is made locally to sp…

This early-stage trial is testing an experimental drug called LP-168, taken as a pill, in adults with B-cell lymphoma that has come back or not responded to standard treatments. The study aims to find the safest dose and check for side effects in about 200 participants. It is too…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to fi…

This study tests a drug called mirdametinib in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The drug blocks a protein that helps cancer cells grow. About 20 participants will take the drug to …

This study tests whether a second type of CAR T-cell therapy, targeting CD22, can extend remission in people with B-cell acute lymphoblastic leukemia who have no signs of cancer after initial CD19 CAR T-cell treatment. About 20 children, adolescents, and adults will receive the m…

This study tests a new way to do stem cell transplants for adults with high-risk blood cancers who don't have a fully matched donor. Doctors will use stem cells from a half-matched (haploidentical) donor and remove certain immune cells to try to prevent severe graft-versus-host d…

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This study compares a new drug, BGB-16673, to an existing one, pirtobrutinib, in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to prior treatment. About 500 adults will be randomly assigned to one of the tw…

This early-phase trial tests whether adding daratumumab (an immunotherapy drug) after a stem cell transplant can safely help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, teens, and young adults up to age 39. About 30 participants will receive the…

This study tests whether adding a targeted drug (nemtabrutinib) to a personalized cell therapy (lisocabtagene maraleucel) can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to treatment. About 20 adults will rec…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase 2 trial tests a gradual, three-drug combination (isatuximab, dexamethasone, and lenalidomide) in 40 ultra-frail patients newly diagnosed with multiple myeloma. The goal is to see if starting treatment slowly improves how well patients tolerate therapy and their quality…

This phase 3 trial is testing whether a new combination of two oral drugs, sonrotoclax and zanubrutinib, works better than the current standard combination (venetoclax plus acalabrutinib) for people with untreated chronic lymphocytic leukemia (CLL). About 500 adults who have not …

This study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This phase 2 trial is testing whether a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that has come back or is resistant to treatment. About 168 adults with high-ri…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 part…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This study tests whether a combination of two non-chemotherapy drugs (vemurafenib and obinutuzumab) causes fewer side effects than the standard chemotherapy-based treatment (cladribine and rituximab) in people with untreated hairy cell leukemia. About 86 adults with a specific ge…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage trial is testing two drugs, mosunetuzumab and venetoclax, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. Mosunetuzumab is given as a shot under the skin, and venetoclax is a daily pill. The study will chec…

This early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…

This early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive suro…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This Phase 1 trial is testing a new type of immunotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not gone away. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack leukem…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe ou…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests a new drug called SLS009, alone or with other medicines, in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also includes newly diagnosed patients with high-risk leukemia. The goal is to see if the drug i…

This phase 2 trial tests pirtobrutinib, an oral BTK inhibitor, in 40 people with chronic lymphocytic leukemia (CLL) whose disease has returned or stopped responding after treatment with zanubrutinib. Researchers will track BTK mutations before, during, and after pirtobrutinib tre…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This Phase 3 trial compares a fixed-duration combination of zanubrutinib and sonrotoclax against continuous zanubrutinib alone in older patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study will enroll 466 participants to see if the combo i…

This trial tests whether giving blinatumomab, a drug that helps the immune system destroy leukemia cells, before a stem cell transplant can improve outcomes for adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). Participants who are in remission and have no detect…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This early-stage trial tests a new antibody drug called 4A10 in 24 people with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma. 4A10 targets a protein on cancer cells to block growth signals and help the immune system attack them. The main goal is…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…

This early-phase trial tests whether giving a second type of CAR T cell therapy (targeting CD22) after the standard CD19 CAR T therapy is safe and feasible for children and young adults with relapsed or hard-to-treat B-cell leukemia. About 20 participants will receive the standar…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This phase 2 trial is testing whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) with relapsed B-cell acute lymphoblastic leukemia (B-ALL), including those with Down syndrome. Blinatumomab helps the immune system find and kill cancer cells, wh…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This phase 2 trial is testing whether combining venetoclax and zanubrutinib can drive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into deep remission. The study enrolls adults who either have not been treated before or whose cancer returned at least two…

This early-stage trial tests a new type of cell therapy for children and young adults up to age 21 with a form of leukemia (CD19-positive) that has returned or not responded to treatment. The therapy uses immune cells from a family donor that are engineered in a lab to recognize …

This study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…

This phase 3 trial tests whether the drug triptorelin can protect the ovaries of adolescents and young adults with cancer who are receiving chemotherapy. Chemotherapy can damage the ovaries, making it hard or impossible to get pregnant later. Triptorelin temporarily pauses ovaria…

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study is looking at how well a combination of two drugs, ibrutinib and venetoclax, works for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Researchers will follow 60 patients who are already scheduled to receive this treatment to see …

This early-phase trial is testing whether a new drug called ORB-021 is safe and tolerable for people with advanced solid tumors who have no standard treatment options left. About 36 adults will receive the drug through an IV to find the best dose for future studies. The main goal…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This trial tests whether a personalized diet and exercise plan during the first month of chemotherapy can make leukemia cells more sensitive to treatment in older children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (B-ALL). The study also aims to redu…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study is for people aged 65 and older with blood cancers who are getting a stem cell transplant. Researchers want to see if giving a lower dose of the drug cyclophosphamide after the transplant can reduce serious side effects while still controlling the cancer. The trial wil…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia w…

This phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This trial investigates a personalized cell therapy called CAR-T for children and young adults (ages 5–50) with B-cell acute lymphoblastic leukemia that has relapsed or not responded to standard treatment. The therapy involves collecting a patient's own immune cells, engineering …

This study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants from around the world will…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-phase trial tests whether stem cell transplants from donors whose tissue type does not fully match the patient can be safe and effective for people with blood cancers who have no other donor options. About 29 adults aged 18-60 will receive chemotherapy followed by the …

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…

This study tests whether giving more doses of the drug abatacept over a longer period can better prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body. About 160 people receiving stem cell transplants from partially ma…

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This study tests a new type of CAR-T cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell acute lymphoblastic leukemia or T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: first, finding the safest …

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive t…

This phase 2 trial is testing a new treatment strategy for adults newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The approach combines a reduced-dose chemotherapy with a full course of the immunotherapy drug blinatumomab, and may a…

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This study looks at whether providing free bags of groceries to patients undergoing stem cell transplants or CAR-T cell therapy can help improve their nutrition and treatment results. Many patients face high medical costs that make it hard to afford enough food, which can hurt th…

This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This study tests a new type of CAR T-cell therapy that uses nanobodies to target two proteins (CD19 and CD22) on leukemia cells. It is for people aged 12 to 65 whose B-cell acute lymphoblastic leukemia has come back or not responded to other treatments. The goal is to see if this…

This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study tests whether a 4-week whole-food plant-based diet can improve immune function and slow disease activity in people with early-stage chronic lymphocytic leukemia (CLL) who have not yet received treatment. Fifty participants will follow the diet and provide blood and sto…

This early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researche…

This early-phase study tests a new treatment called OC-1, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack a specific marker (CD1a) on cancer cells. The trial aims to see if this therapy is safe and can help shrink or elim…

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This study tests whether adding the experimental drug capivasertib to a standard treatment (venetoclax plus low-intensity chemotherapy) is safe and effective for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to prior …

This early-stage trial tests a new type of CAR T-cell therapy (CMD63) in 16 children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy uses specially engineered immune cells to target and kill cancer cells. The main goal i…

This pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…

This study tests a personalized cell therapy called CAR T-cells for people with relapsed or hard-to-treat lymphoma or acute lymphoblastic leukemia (ALL). The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusin…

This study tests whether adding newer antibody-based drugs to standard chemotherapy can improve survival and reduce the need for stem cell transplants in adults with acute lymphoblastic leukemia (ALL). About 1,200 patients aged 18–65 with newly diagnosed ALL will be assigned to o…

This study tests a drug called tafasitamab in children aged 3 to 17 with B-cell leukemia that has come back or not responded to treatment. The drug is an antibody that helps the immune system find and kill leukemia cells. The trial has two parts: first, finding the best dose, and…

This study compares two different dosing schedules of the blood thinner apixaban (Eliquis) against no blood thinner in about 996 cancer patients at moderate risk for blood clots. Participants take either 2.5 mg twice daily, 5 mg once daily, or no anticoagulant for 6 months. The g…

This phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…

This phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…

This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…

This early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…

This study tests two different pre-transplant conditioning plans combined with a single drug combination (cyclophosphamide and methotrexate) to prevent graft-versus-host disease (GVHD) in blood cancer patients receiving a stem cell transplant from a matched donor. About 82 adults…

This phase 2 trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in 30 adults with blood cancer who are receiving a stem cell transplant from a donor. These patients are at high risk because of newer transplant methods. The study will check …

This study is testing a new type of immunotherapy called CAR T cells for adults (ages 18-75) with a hard-to-treat blood cancer called acute lymphoblastic leukemia (ALL) that has come back or not responded to standard treatments. The treatment involves taking a patient's own immun…

This early study tests a new cell therapy called GK01, made from a patient's own immune cells, for advanced solid tumors. Fifteen participants will receive GK01 alone or with chemotherapy after surgery. The main goal is to check safety, not yet to prove it works.

This study tests whether giving radiotherapy early to high-risk bone metastases that are not yet causing symptoms can prevent future bone complications like fractures. About 120 adults with solid tumors and at least three bone metastases will be randomly assigned to either standa…

This early-stage trial tests an oral drug called AUR112 in 40 adults with relapsed advanced lymphoma. The main goals are to check safety, find the right dose, and see how the drug moves through the body. It is the first time this drug is being tested in humans.

This study tests whether a drug called tranexamic acid can safely replace routine platelet transfusions in adults receiving a stem cell transplant for blood cancers. About 662 participants will either get tranexamic acid or standard platelet transfusions. The goal is to see if th…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not improved after standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra…

This study tests whether taking the targeted drug venetoclax on an intermittent schedule (with breaks) works as well as taking it continuously, when combined with acalabrutinib, in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About …

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…

This study tests a higher dose of a molecule called UM171 to grow more stem cells from donated cord blood for transplant. It is for adults with high-risk blood cancers like leukemia who have no suitable donor. The goal is to help patients recover blood counts faster, reduce infec…

This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is.…

This study tests a dose-adjusted chemotherapy regimen for adults with acute lymphoblastic leukemia who are too frail for standard treatment. The goal is to improve survival and reduce severe side effects. About 45 participants will receive an infusion-based therapy designed to be…

This study tests whether a fecal microbiota transplant (FMT) combined with the immunotherapy drug nivolumab can help people with advanced solid cancers that stopped responding to prior treatment. About 50 participants will receive the combination to see if it can shrink tumors. T…

This study tests whether a tailored exercise program combined with a dietary supplement called nicotinamide riboside (NR) can improve muscle mass, strength, and fitness in adolescents and young adults who had a bone marrow transplant for leukemia or other blood disorders. About 8…

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This study looks at whether a special brain wave monitor (EEG) can help doctors choose the right amount of sedation medicine for children who need a brain MRI. About 50 children under 5 years old (or older children who have trouble staying still) will receive a standard low dose …

This study is testing a new platform that uses advanced testing to get a complete picture of a person's tumor. The goal is to see if this detailed information can help doctors choose better treatments for patients with high-risk cancers like leukemia, multiple myeloma, and pancre…

This study tests a new, high-resolution ultrasound technique called Ultrasound Localization Microscopy (ULM) to detect early kidney damage in children who have been treated for acute lymphoblastic leukemia (ALL). The method uses tiny bubbles (contrast agent) to see blood flow in …

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

Researchers are testing inotuzumab ozogamicin, an antibody-drug conjugate, in people with CD22-positive acute lymphocytic leukemia who have already had a stem cell transplant. The trial has two parts: a phase 1 portion to find the highest dose that is safe to give after transplan…

This trial tests whether a 14-week nature-based program, integrated into kindergarten routines, can enhance mental and physical well-being in children aged 4-6 from deprived areas. It will compare the program to usual activities, measuring outcomes like motor skills, physical act…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This phase 3 trial is testing whether adding Gamunex-C (an immune globulin) to standard care can prevent serious infections in people with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma. About 49 participants will receive Gamunex-C through an IV every 4 w…

This study looks at how well the shingles vaccine works in people with weakened immune systems, such as those with cancer or autoimmune diseases. Researchers will measure immune responses and track side effects in 300 adults. The goal is to see if the vaccine can effectively prev…

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This trial tests whether a dedicated 'return-to-work after cancer' consultation can help people who have been treated for blood cancers like leukemia, lymphoma, or multiple myeloma get back to their jobs. The consultation, led by an occupational health specialist with possible su…

This study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

This study tests whether a 9-week strength training program using resistance bands and body weight exercises is practical for children aged 6-21 newly diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. The program combines at-home exercises with optional Zoom …

This phase II trial tests whether a plant-derived supplement called chlorophyllin can reduce severe mouth sores caused by high-dose radiation given before a stem cell transplant. People aged 12 to 65 with blood cancers who need total body irradiation as part of their transplant p…

This study tests whether modafinil, a drug that promotes wakefulness, can reduce severe fatigue and thinking problems in people with advanced cancer. About 40 adults with stage III or IV cancer will receive either modafinil or a placebo for a short time. The goal is to see if the…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This pilot study tests whether a physical activity program can help children aged 5–17 with acute lymphoblastic leukemia maintain muscle strength and avoid frailty during early treatment. Kids who show signs of weakness after five weeks of chemotherapy are randomly assigned to ei…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This study tests whether a virtual reality treadmill program can improve motor and cognitive function in adults up to age 75. Participants will walk on a 360-degree treadmill while wearing a VR headset, doing daily-life tasks like grocery shopping. The goal is to see if this trai…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study tests a program called Sentinel that trains stem cell transplant doctors to provide palliative care—like managing symptoms and coping strategies—as part of routine care. The goal is to see if it's feasible and acceptable for patients. Forty adults undergoing stem cell …

This study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…

This study tests whether a computer brain-training program (Lumosity) can improve memory and thinking in adults who had a stem cell transplant for blood cancer. About 60 survivors, 3 to 6 months after transplant, will either start training right away or wait 12 weeks. The goal is…

This study aims to find out which parts of behavioral therapy work best for children aged 8-17 with PTSD after a traumatic event. Researchers will compare different therapy components, like emotion regulation and exposure, to a placebo. 200 children and their caregivers will part…

This study tests a mobile app called THRIVE-CAR-T designed to support patients during CAR-T cell therapy. Researchers want to see if the app is easy to use and acceptable to patients. About 100 adults with blood cancer receiving CAR-T treatment will participate. The app provides …

This study tests whether live, group-based exercise classes held over Zoom can help cancer survivors increase their physical activity, improve fitness, and enhance quality of life. Researchers will randomly assign 300 cancer survivors to either live online classes or recorded exe…

This study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…

This study tests whether online cognitive training and mindfulness can help children aged 8-18 who had leukemia and received intensive treatments like CAR-T therapy, chemotherapy, or a stem cell transplant. Forty participants will do brain exercises and mindfulness sessions from …

This study tests whether a program of targeted exercise and psychological support before cancer treatment (called prehabilitation) can help patients with solid tumors recover better physically and emotionally. Researchers will compare this program to standard care in 125 adults w…

This study tests a special rehab program for adults with blood cancer who are getting a bone marrow transplant. The program includes exercise, nutrition support, and self-management skills starting before the transplant and continuing for 6 months after. Researchers want to see i…

This study tests whether a cream containing tretinoin (a form of vitamin A) can prevent or reduce the acne-like rash that often occurs in patients taking certain cancer drugs. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo …

This study tests if a home-based program of laughter and fun yoga can lower pain in children aged 2-10 with acute lymphoblastic leukemia who are receiving chemotherapy. Sixty participants will be randomly assigned to either the laughter and yoga program plus usual care, or usual …

This study tests whether remote health education workshops are feasible for adolescents and young adults with cancer. Participants will attend three online sessions designed to help them manage their disease and treatment. The goal is to see if patients stick with the program and…

This study tests a new support program called WorkS for people who have had a stem cell transplant and are worried about going back to work. About 35 participants will receive coaching sessions to help them feel more confident and manage work-related challenges. The goal is to se…

This study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This study uses non-invasive MRI and MRS scans to measure how well muscle cells produce energy in adults who survived childhood acute lymphoblastic leukemia (ALL). Researchers will compare 60 survivors with low muscle mass to healthy volunteers. The goal is to understand why many…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…

This study tests whether a video and personal guidance can help Black, Latinx, and older adults with cancer get genetic testing. Genetic testing is often needed to join precision cancer trials. The goal is to make trial enrollment more equitable. About 210 people with gastrointes…

Researchers at Peking University First Hospital are building a prospective cohort of 2,000 people with plasma cell disorders, including multiple myeloma, amyloidosis, and related conditions. Participants give blood, bone marrow, and urine samples before and after treatment, and t…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study follows up to 1,000 adults with certain slow-growing blood cancers (CLL, SLL, LPL, WM) to track how the diseases change over time. Participants have regular check-ups and blood draws every 6 to 24 months, and may also have optional biopsies or scans for research. No tr…

This study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and w…

Researchers in China are reviewing medical records of 500 children diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) between 2015 and 2024. The study compares diagnosis, treatment, and survival outcomes, including a subtype called CML-like ALL…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study observes about 350 people with chronic lymphocytic leukemia (CLL) who received the drug acalabrutinib through a UK early access program. Researchers will review medical records to see how long patients went without their cancer worsening and how long they lived. No new…

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib (with or without obinutuzumab). Researchers will track hospital visits, quality of life, and how well the d…

This study tracks 50 adults with chronic lymphocytic leukemia (CLL) who are starting acalabrutinib alone (no other cancer drugs) to see how long they stay on treatment and why they might stop. It collects real-world data on effectiveness and side effects, filling a knowledge gap …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks at whether giving fiber supplements to patients undergoing donor stem cell transplants is practical and well-tolerated. The goal is to see if fiber can support nutrition and gut health after the harsh effects of chemotherapy and radiation. The trial will enroll 4…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study looks at whether a simple blood test can track how well treatment is working in children with acute lymphoblastic leukemia (ALL). Currently, doctors must take bone marrow samples to check for leftover cancer cells, which is invasive and painful. The researchers will co…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study is testing whether wearable activity trackers like Fitbits and iPhones can help predict when cancer patients undergoing radiation therapy might need emergency care or hospitalization. Researchers will collect step counts and other health data from 260 participants to b…

This study follows people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who previously received a combination of ibrutinib and venetoclax in the CAPTIVATE trial. Researchers will track their health for up to 10 years to see what treatments they need …

This study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study follows children and young adults with acute lymphoblastic leukemia (ALL) who receive CAR-T cell therapy. The goal is to track how long these engineered immune cells persist in the body and identify factors that cause them to disappear. By understanding why CAR-T cells…

This study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…

This study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…

This study tests whether a survivorship care plan is practical for blood cancer patients who have had a stem cell transplant. Researchers will track how many patients stick with the program and measure their quality of life, unmet needs, and caregiver burden. The goal is to see i…

This study follows 400 people in Norway with multiple myeloma, plasma cell leukemia, or AL amyloidosis who are receiving newer immunotherapies like teclistamab, elranatamab, or CAR-T cell therapy outside of clinical trials. Researchers will track how well these treatments control…

This study tests a web-based decision-support tool designed to help families and doctors make shared decisions about whether a child should go on chronic home ventilation. Half of the participating families use the tool, while the other half receive usual care. Researchers then m…

This study aims to make clinical trials more inclusive by training 40 adults who are in remission from blood cancer to review and give feedback on trial plans. The goal is to see if this community-based review process is practical and acceptable. The study does not test a new tre…

This study investigates the long-term heart and lung health of adults who survived childhood acute lymphoblastic leukemia (ALL) or lymphoma. Researchers use advanced MRI and other imaging to detect subtle damage from past chemotherapy, comparing survivors to healthy volunteers. T…

This study looks at whether blood cancer patients with a serious infection can safely stop antibiotics sooner if they are stable for 72 hours, instead of the usual 10-day course. About 172 adults will be randomly assigned to either a personalized short course or standard long cou…

This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…

This study follows adults aged 18 and older who have a specific type of acute lymphoblastic leukemia (Ph+ ALL) and are receiving a combination of targeted drugs (BCR::ABL1 inhibitors) along with chemotherapy, steroids, or antibody therapy. Researchers will track how long patients…

This study creates a registry for people with hairy cell leukemia (HCL), a rare form of adult leukemia. Researchers will track disease course, treatments, infections, and patient-reported outcomes over time. The goal is to identify trends, improve care, and design future clinical…

This study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…

This study gathers information from 50 people with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive blood cancer. Researchers will look at patients' medical records, lab results, and genetic data to better understand the disease and how it responds to current treatme…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study collects extra blood and bone marrow samples from people receiving CAR-T cell therapy for lymphoma or acute lymphoblastic leukemia. The goal is to build a biobank that researchers can use to investigate why about half of patients do not respond to this treatment. Parti…

This study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study looks at whether we can safely remove the "beta-lactam allergy" label from blood cancer patients who are not truly allergic. By doing so, doctors can use more effective antibiotics. The study will enroll 3,800 hospitalized adults with blood cancers and a reported aller…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive chang…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study follows 1,400 children and teens (ages 3-21) in Southern Europe with acute lymphoblastic leukemia or certain brain tumors. Researchers will track their diet, lifestyle, and quality of life over time to see how these factors relate to treatment side effects and survival…

This study is creating a collection of blood and bone marrow samples from 1,000 adults with acute myeloid leukemia, acute lymphoblastic leukemia, or high-risk myelodysplastic syndrome. The samples will be used by researchers to better understand these diseases and find new ways t…

This study collects blood and tumor samples from 700 adults receiving approved CAR-T therapy for blood cancers. Researchers will analyze these samples to identify biological markers that predict whether the therapy will work or if the cancer will return. The goal is to improve fu…

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study looks at how often children with leukemia or lymphoma develop a shortage of natural stress hormones after high-dose steroid treatment. Researchers will test 40 children during and after therapy to see how long the deficiency lasts and who is most at risk. The goal is t…

This study is testing whether a new wireless skin sensor system can safely and accurately monitor the heart rate, breathing, oxygen levels, and temperature of healthy newborns right after birth. 600 babies will wear both the wireless sensors and standard wired monitors for the fi…

This observational study follows 2,000 people with chronic lymphocytic leukemia (CLL) who have completed first-line treatment in earlier clinical trials. Researchers will collect data from routine care to see how different treatment sequences affect overall survival, quality of l…

This study tests whether a special PET scan (18F FLT) can detect signs of leukemia or myeloma after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat blood cancers will get the scan before and after therapy. Researchers will compare the scan results with stan…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This observational study looks at whether leukemia stem cells can predict if acute myeloid leukemia (AML) with MLL rearrangement will come back. Researchers will measure these stem cells in bone marrow samples taken during regular check-ups. The goal is to improve relapse predict…

This study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…

This study follows children and teens who had radiation to the brain before age 16 to check for hormone problems. Researchers will measure hormone levels and track fatigue to create better follow-up guidelines. About 230 participants in remission from cancer will be monitored for…

This study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…

This study will analyze the genes of 25,000 adults who have cancer or are at risk for it. Researchers will use advanced testing to find genetic changes linked to cancer and track health records over time. The goal is to learn more about cancer biology and discover new ways to per…

This registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…

This study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…

This study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…

This study will collect blood and tumor samples from 20,000 adults with solid tumors to perform detailed genetic analysis. The goal is to find how many patients have at least one genetic change that could be targeted by existing or experimental therapies. This is a research study…

This study tests whether newer imaging techniques like special ultrasound and MRI can detect heart damage earlier in children, adolescents, and young adults who have had cancer treatment. Researchers will follow 400 participants to see how many develop heart problems. The goal is…

This study is gathering information from 500 cancer patients treated with proton therapy, a type of radiation that may cause fewer side effects than standard radiation. Researchers want to see how well it works in everyday practice and track any side effects. The goal is to build…

This study is observing 500 Indian children with acute lymphoblastic leukemia (ALL) to see how their genes influence treatment side effects and how well they respond to therapy. Researchers will track side effects and measure early response to steroids. The goal is to better unde…

This study aims to find immune system markers that can predict how well a cancer patient responds to radiotherapy. Researchers will analyze blood samples from 40 adults who have already completed radiotherapy without major side effects. The goal is to personalize future cancer tr…

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This study looks at why 20% of children with B-cell acute lymphoblastic leukemia (B-ALL) relapse after treatment. Researchers will collect bone and blood samples from 50 newly diagnosed children at three key points during therapy. They will study how a protein called CD9 is regul…

This study looks at a protein called LEF-1 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if measuring LEF-1 can help make a more accurate diagnosis and find new clues about the disease. They will study tissue sample…

This study compares a continuous heart-monitoring patch with standard electrocardiograms (ECGs) in 60 adults receiving cancer drugs that can cause dangerous heart rhythm changes. The goal is to see if the patch detects problems more accurately and consistently. Participants will …

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…

This study collects and stores blood and tissue samples from 6,000 people with multiple myeloma and related conditions like smoldering myeloma and MGUS. The goal is to create a shared resource for researchers worldwide to study these diseases and improve patient care. Participant…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study looks at bone marrow cells from children with acute leukemia and compares them to cells from children without blood diseases. The goal is to understand why some leukemias relapse or resist treatment. Researchers will measure how these cells use energy and handle stress…